company background image
CRSP

CRISPR TherapeuticsNasdaqGM:CRSP Stock Report

Last Price

US$67.77

Market Cap

US$5.2b

7D

-1.9%

1Y

-66.1%

Updated

17 Jan, 2022

Data

Company Financials +
CRSP fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

CRSP Stock Overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.

CRISPR Therapeutics Competitors

Editas Medicine

NasdaqGS:EDIT

US$1.5b

Sangamo Therapeutics

NasdaqGS:SGMO

US$932.3m

Caribou Biosciences

NasdaqGS:CRBU

US$698.8m

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share PriceUS$67.77
52 Week HighUS$208.18
52 Week LowUS$64.76
Beta2.05
1 Month Change-18.08%
3 Month Change-32.41%
1 Year Change-66.10%
3 Year Change82.52%
5 Year Change265.53%
Change since IPO380.98%

Recent News & Updates

Jan 14

Crispr Therapeutics' Giant Leap For Humankind

Crispr Therapeutics uses a technology called Crispr-Cas9 to edit genes. Crispr-Cas9 allows gene editing to be cheap, fast, and accurate creating massive potentials for Crispr Therapeutics. Gene-based diseases like Sickle Cell Disease may finally be treatable. However, because the company is in the pre-revenue stage with questionable future scalability and margins, I think it is better for investors to stay on the sidelines and hope that this revolutionary technology helps the people in need.

Dec 15

Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration

CRISPR Therapeutics is a gene therapy company pioneering the CRISPR/Cas9 gene editing tool, discovered by its scientific co-founder. The company is partnered with Vertex - a $58bn market cap biotech with >$6bn in cash - on its lead program in Sickle Cell Disease. An approval could be in the offing - bluebird is its chief rival, but 2 gene therapy approvals may not damage the >$1bn peak sales potential. In-vivo gene therapies and allogeneic cell therapies are an important part of CRISPR's pipeline also, a few years further back in the development process but exciting nonetheless. It's hard to explain why CRISPR shares have lost ~65% of their value since January, but it offers an opportunity to build a position in a biotech with downside protection, a $2.5bn cash position, and some potentially transformative therapies.

Dec 02

Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair Valuation

One of the company's co-founders won a Nobel prize in chemistry for her work done on the CRISPR technology. The company has revolutionary technology but is in the early stages of development. The company is currently valuated at half of its high from less than six months ago.

Nov 22

CRISPR's Life-Saving Technology Has Massive Potential

CRISPR Therapeutics AG is a pre-revenue company specializing in CRISPR-Cas9. It allows accurate genetic replacement of the disease-associated DNA. CTX001 is the treatment candidate for Sickle Cell Disease and Beta-Thalassemia from the collaboration between CRSP and Vertex Pharmaceuticals Incorporated. CTX001 has shown sustained positive results in its phase 1/2 clinical trials. We discuss whether investors should add CRSP stock now.

Shareholder Returns

CRSPUS BiotechsUS Market
7D-1.9%-2.5%-0.3%
1Y-66.1%-14.3%13.7%

Return vs Industry: CRSP underperformed the US Biotechs industry which returned -14.3% over the past year.

Return vs Market: CRSP underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement8.2%
Biotechs Industry Average Movement10.0%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CRSP's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013410Sam Kulkarnihttps://www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

CRISPR Therapeutics Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
CRSP fundamental statistics
Market CapUS$5.19b
Earnings (TTM)US$411.87m
Revenue (TTM)US$902.43m

12.6x

P/E Ratio

5.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRSP income statement (TTM)
RevenueUS$902.43m
Cost of RevenueUS$386.53m
Gross ProfitUS$515.91m
ExpensesUS$104.04m
EarningsUS$411.87m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)5.38
Gross Margin57.17%
Net Profit Margin45.64%
Debt/Equity Ratio0%

How did CRSP perform over the long term?

See historical performance and comparison

Valuation

Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?

47.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CRSP ($67.77) is trading below our estimate of fair value ($128.77)

Significantly Below Fair Value: CRSP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CRSP is good value based on its PE Ratio (12.6x) compared to the US Biotechs industry average (24.4x).

PE vs Market: CRSP is good value based on its PE Ratio (12.6x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: CRSP is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: CRSP is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.2x).


Future Growth

How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

15.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRSP's forecast earnings growth (15.7% per year) is above the savings rate (2%).

Earnings vs Market: CRSP's earnings (15.7% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: CRSP's earnings are forecast to grow, but not significantly.

Revenue vs Market: CRSP's revenue (21.4% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: CRSP's revenue (21.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRSP is forecast to be unprofitable in 3 years.


Past Performance

How has CRISPR Therapeutics performed over the past 5 years?

16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CRSP has high quality earnings.

Growing Profit Margin: CRSP became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by 16% per year.

Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: CRSP's Return on Equity (16.4%) is considered low.


Financial Health

How is CRISPR Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CRSP's short term assets ($2.5B) exceed its short term liabilities ($96.2M).

Long Term Liabilities: CRSP's short term assets ($2.5B) exceed its long term liabilities ($212.6M).


Debt to Equity History and Analysis

Debt Level: CRSP is debt free.

Reducing Debt: CRSP had no debt 5 years ago.

Debt Coverage: CRSP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CRSP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRSP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Sam Kulkarni (42 yo)

4.08yrs

Tenure

US$9,105,256

Compensation

Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Centessa Pharmaceuticals Lim...


CEO Compensation Analysis

Compensation vs Market: Sam's total compensation ($USD9.11M) is above average for companies of similar size in the US market ($USD6.40M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CRSP's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: CRSP's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.3%.


Top Shareholders

Company Information

CRISPR Therapeutics AG's employee growth, exchange listings and data sources


Key Information

  • Name: CRISPR Therapeutics AG
  • Ticker: CRSP
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.186b
  • Shares outstanding: 76.53m
  • Website: https://www.crisprtx.com

Number of Employees


Location

  • CRISPR Therapeutics AG
  • Baarerstrasse 14
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/17 23:19
End of Day Share Price2022/01/14 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.